MedTrace Logo

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

NCT02471716 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-08-31

Study results available
· View outcomes & findings →

Summary

This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.

Conditions

  • Pigmented Villonodular Synovitis
  • Tenosynovial Giant Cell Tumor

Interventions

BIOLOGICAL

FPA008

FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks

Sponsors & Collaborators

  • Five Prime Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Lead · Five Prime Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • United States
  • France
  • Netherlands
  • Poland
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02471716 on ClinicalTrials.gov